Transgenic human C-reactive protein affects oxidative stress but not inflammation biomarkers in the aorta of spontaneously hypertensive rats.
Aorta
C-reactive protein
Endothelial dysfunction
Oxidative stress
Spontaneously hypertensive rat
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
09
11
2023
accepted:
30
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
C-reactive protein (CRP) is an acute inflammatory protein detected in obese patients with metabolic syndrome. Moreover, increased CRP levels have been linked with atherosclerotic disease, congestive heart failure, and ischemic heart disease, suggesting that it is not only a biomarker but also plays an active role in the pathophysiology of cardiovascular diseases. Since endothelial dysfunction plays an essential role in various cardiovascular pathologies and is characterized by increased expression of cell adhesion molecules and inflammatory markers, we aimed to detect specific markers of endothelial dysfunction, inflammation, and oxidative stress in spontaneously hypertensive rats (SHR) expressing human CRP. This model is genetically predisposed to the development of the metabolic syndrome. Transgenic SHR male rats (SHR-CRP) and non-transgenic SHR (SHR) at the age of 8 months were used. Metabolic profile (including serum and tissue triglyceride (TAG), serum insulin concentrations, insulin-stimulated incorporation of glucose, and serum non-esterified fatty acids (NEFA) levels) was measured. In addition, human serum CRP, MCP-1 (monocyte chemoattractant protein-1), and adiponectin were evaluated by means of ELISA, histological analysis was used to study morphological changes in the aorta, and western blot analysis of aortic tissue was performed to detect expression of endothelial, inflammatory, and oxidative stress markers. The presence of human CRP was associated with significantly decreased insulin-stimulated glycogenesis in skeletal muscle, increased muscle and hepatic accumulation of TAG and decreased plasmatic cGMP concentrations, reduced adiponectin levels, and increased monocyte chemoattractant protein-1 (MCP-1) levels in the blood, suggesting pro-inflammatory and presence of multiple features of metabolic syndrome in SHR-CRP animals. Histological analysis of aortic sections did not reveal any visible morphological changes in animals from both SHR and SHR-CRP rats. Western blot analysis of the expression of proteins related to the proper function of endothelium demonstrated significant differences in the expression of p-eNOS/eNOS in the aorta, although endoglin (ENG) protein expression remained unaffected. In addition, the presence of human CRP in SHR in this study did not affect the expression of inflammatory markers, namely p-NFkB, P-selectin, and COX2 in the aorta. On the other hand, biomarkers related to oxidative stress, such as HO-1 and SOD3, were significantly changed, indicating the induction of oxidative stress. Our findings demonstrate that CRP alone cannot fully induce the expression of endothelial dysfunction biomarkers, suggesting other risk factors of cardiovascular disorders are necessary to be involved to induce endothelial dysfunction with CRP.
Sections du résumé
BACKGROUND
BACKGROUND
C-reactive protein (CRP) is an acute inflammatory protein detected in obese patients with metabolic syndrome. Moreover, increased CRP levels have been linked with atherosclerotic disease, congestive heart failure, and ischemic heart disease, suggesting that it is not only a biomarker but also plays an active role in the pathophysiology of cardiovascular diseases. Since endothelial dysfunction plays an essential role in various cardiovascular pathologies and is characterized by increased expression of cell adhesion molecules and inflammatory markers, we aimed to detect specific markers of endothelial dysfunction, inflammation, and oxidative stress in spontaneously hypertensive rats (SHR) expressing human CRP. This model is genetically predisposed to the development of the metabolic syndrome.
METHODS
METHODS
Transgenic SHR male rats (SHR-CRP) and non-transgenic SHR (SHR) at the age of 8 months were used. Metabolic profile (including serum and tissue triglyceride (TAG), serum insulin concentrations, insulin-stimulated incorporation of glucose, and serum non-esterified fatty acids (NEFA) levels) was measured. In addition, human serum CRP, MCP-1 (monocyte chemoattractant protein-1), and adiponectin were evaluated by means of ELISA, histological analysis was used to study morphological changes in the aorta, and western blot analysis of aortic tissue was performed to detect expression of endothelial, inflammatory, and oxidative stress markers.
RESULTS
RESULTS
The presence of human CRP was associated with significantly decreased insulin-stimulated glycogenesis in skeletal muscle, increased muscle and hepatic accumulation of TAG and decreased plasmatic cGMP concentrations, reduced adiponectin levels, and increased monocyte chemoattractant protein-1 (MCP-1) levels in the blood, suggesting pro-inflammatory and presence of multiple features of metabolic syndrome in SHR-CRP animals. Histological analysis of aortic sections did not reveal any visible morphological changes in animals from both SHR and SHR-CRP rats. Western blot analysis of the expression of proteins related to the proper function of endothelium demonstrated significant differences in the expression of p-eNOS/eNOS in the aorta, although endoglin (ENG) protein expression remained unaffected. In addition, the presence of human CRP in SHR in this study did not affect the expression of inflammatory markers, namely p-NFkB, P-selectin, and COX2 in the aorta. On the other hand, biomarkers related to oxidative stress, such as HO-1 and SOD3, were significantly changed, indicating the induction of oxidative stress.
CONCLUSIONS
CONCLUSIONS
Our findings demonstrate that CRP alone cannot fully induce the expression of endothelial dysfunction biomarkers, suggesting other risk factors of cardiovascular disorders are necessary to be involved to induce endothelial dysfunction with CRP.
Identifiants
pubmed: 38627621
doi: 10.1186/s12872-024-03870-7
pii: 10.1186/s12872-024-03870-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Subventions
Organisme : Program EXCELES
ID : LX22NPO5104
Organisme : Specific University Research
ID : SVV 260 633
Organisme : EFSA-CDN
ID : CZ.02.1.01/0.0/0.0/16_019/0000841
Informations de copyright
© 2024. The Author(s).
Références
Ridker PM, Silvertown JD, Inflammation. C-reactive protein, and atherothrombosis. Journal of periodontology. 2008;79(8 Suppl):1544-51. https://doi.org/10.1902/jop.2008.080249 . PubMed PMID: 18673009.
Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol. 2005;20(5):407–16. PubMed PMID: 16093760.
pubmed: 16093760
Keaney JF. Jr. Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. Mol Aspects Med. 2000;21(4–5):99–166. Epub 2000/10/25. https://doi.org/10.1016/S0098-2997(00)00005-4 [pii]. PubMed PMID: 11044550.
doi: 10.1016/S0098-2997(00)00005-4
pubmed: 11044550
Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243(2):383–8. https://doi.org/10.1016/j.atherosclerosis.2015.10.003 . Epub 2015/11/02.
doi: 10.1016/j.atherosclerosis.2015.10.003
pubmed: 26520890
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32. PubMed PMID: 15198963.
pubmed: 15198963
Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106(12):1439–41. PubMed PMID: 12234944.
doi: 10.1161/01.CIR.0000033116.22237.F9
pubmed: 12234944
Iacoviello L, Donati MB, de Gaetano G. [Novel risk factors for atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and cholesterol as predictors of peripheral arteriopathy]. Ital Heart J Suppl. 2001;2(9):1031–3. PubMed PMID: 11675827.
pubmed: 11675827
Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J. 2010;31(17):2087–91. https://doi.org/10.1093/eurheartj/ehq238 . PubMed PMID: 20685682.
doi: 10.1093/eurheartj/ehq238
pubmed: 20685682
Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–908. doi: 10.1056/NEJMoa0707402. PubMed PMID: 18971492.
doi: 10.1056/NEJMoa0707402
pubmed: 18971492
Abramson JL, Hooper WC, Jones DP, Ashfaq S, Rhodes SD, Weintraub WS, et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis. 2005;178(1):115–21. PubMed PMID: 15585208.
doi: 10.1016/j.atherosclerosis.2004.08.007
pubmed: 15585208
Durante W. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Front Biosci. 2012;17:2372–88. Epub 2011/05/31. https://doi.org/10.2741/3860 [pii]. PubMed PMID: 21622183.
Hosick PA, Stec DE. Heme oxygenase, a novel target for the treatment of hypertension and obesity? Am J Physiol Regul Integr Comp Physiol. 2012;302(2):R207-14. Epub 2011/11/11. https://doi.org/10.1152/ajpregu.00517.2011 [pii]. PubMed PMID: 22071158.
Pravenec M, Kajiya T, Zidek V, Landa V, Mlejnek P, Simakova M, et al. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 2011;57(4):731–7. https://doi.org/10.1161/HYPERTENSIONAHA.110.164350 . PubMed PMID: 21357282; PubMed Central PMCID: PMC3060762.
doi: 10.1161/HYPERTENSIONAHA.110.164350
pubmed: 21357282
Silhavy J, Mlejnek P, Simakova M, Malinska H, Markova I, Huttl M, et al. Hypolipidemic effects of beetroot juice in SHR-CRP and HHTg rat models of metabolic syndrome: analysis of hepatic proteome. Metabolites. 2023;13(2). https://doi.org/10.3390/metabo13020192 . Epub 20230128.
Tejera-Munoz A, Guerra-Menendez L, Amor S, Gonzalez-Hedstrom D, Garcia-Villalon AL, Granado M. Postnatal overfeeding during lactation induces endothelial dysfunction and cardiac insulin resistance in adult rats. Int J Mol Sci. 2023;24(19). https://doi.org/10.3390/ijms241914443 . Epub 20230922.
Brazao SC, Lima GF, Autran LJ, Mendes ABA, Dos Santos BA, Magliano DC, et al. Subacute administration of cilostazol modulates PLC-gamma/PKC-alpha/p38/NF-kB pathway and plays vascular protective effects through eNOS activation in early stages of atherosclerosis development. Life Sci. 2023;332:122082. https://doi.org/10.1016/j.lfs.2023.122082 . Epub 20230916.
doi: 10.1016/j.lfs.2023.122082
pubmed: 37722587
Nemeckova I, Serwadczak A, Oujo B et al. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS ONE. 2015:e0119665.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784–92. https://doi.org/10.1172/JCI29126 . PubMed PMID: 16823476; PubMed Central PMCID: PMCPMC1483172.
doi: 10.1172/JCI29126
pubmed: 16823476
pmcid: 1483172
Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Reviews Endocr Metabolic Disorders. 2014;15(2):157–67. https://doi.org/10.1007/s11154-013-9265-5 . PubMed PMID: 24019064.
doi: 10.1007/s11154-013-9265-5
Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol. 2007;210(2):456–68. PubMed PMID: 17058229.
doi: 10.1002/jcp.20878
pubmed: 17058229
Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15–25. https://doi.org/10.1016/j.atherosclerosis.2018.02.008 . PubMed PMID: 29459262.
doi: 10.1016/j.atherosclerosis.2018.02.008
pubmed: 29459262
Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007;14(2):243–8. Epub 2007/02/03. PubMed PMID: 17266583.
doi: 10.2174/092986707779313381
pubmed: 17266583
Araujo JA, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol. 2012;3:119. https://doi.org/10.3389/fphar.2012.00119 . Epub 2012/07/27.
doi: 10.3389/fphar.2012.00119
pubmed: 22833723
pmcid: 3400084
Lund DD, Gunnett CA, Chu Y, Brooks RM, Faraci FM, Heistad DD. Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin. Am J Physiol Heart Circ Physiol. 2004;287(2):H805–11. https://doi.org/10.1152/ajpheart.00907.2003 . PubMed PMID: 15277203.
doi: 10.1152/ajpheart.00907.2003
pubmed: 15277203
Iida S, Chu Y, Francis J, Weiss RM, Gunnett CA, Faraci FM, et al. Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005;289(2):H525–32. https://doi.org/10.1152/ajpheart.00108.2005 . PubMed PMID: 16014615.
doi: 10.1152/ajpheart.00108.2005
pubmed: 16014615
Foresman EL, Miller FJ. Jr. Extracellular but not cytosolic superoxide dismutase protects against oxidant-mediated endothelial dysfunction. Redox Biol. 2013;1:292–6. https://doi.org/10.1016/j.redox.2013.04.003 . PubMed PMID: 24024163; PubMed Central PMCID: PMC3757697.
doi: 10.1016/j.redox.2013.04.003
pubmed: 24024163
pmcid: 3757697